ZHX1

Summary

ZHX1 (zinc fingers and homeoboxes 1, HGNC:12871) is a protein-coding gene on chromosome 8q24.13, encoding Zinc fingers and homeoboxes protein 1 (Q9UKY1). Acts as a transcriptional repressor.

The members of the zinc fingers and homeoboxes gene family are nuclear homodimeric transcriptional repressors that interact with the A subunit of nuclear factor-Y (NF-YA) and contain two C2H2-type zinc fingers and five homeobox DNA-binding domains. This gene encodes member 1 of this gene family. In addition to forming homodimers, this protein heterodimerizes with members 2 and 3 of the zinc fingers and homeoboxes family. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream chromosome 8 open reading frame 76 (C8orf76) gene.

Source: NCBI Gene 11244 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 101 total
• MANE Select transcript: NM_007222

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12871
Approved symbol	ZHX1
Name	zinc fingers and homeoboxes 1
Location	8q24.13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000165156
Ensembl biotype	protein_coding
OMIM	604764
Entrez	11244

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 22 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000297857, ENST00000395571, ENST00000480132, ENST00000517516, ENST00000522595, ENST00000522655, ENST00000524267, ENST00000602651, ENST00000863173, ENST00000863174, ENST00000863175, ENST00000863176, ENST00000863177, ENST00000863178, ENST00000863179, ENST00000863180, ENST00000863181, ENST00000863182, ENST00000863183, ENST00000863184, ENST00000863185, ENST00000956169, ENST00000956170, ENST00000956171, ENST00000956172, ENST00000956173

RefSeq mRNA: 2 — MANE Select: NM_007222 NM_001017926, NM_007222

CCDS: CCDS6342

Canonical transcript exons

ENST00000395571 — 4 exons

Exon	Start	End
ENSE00001090837	123253322	123256171
ENSE00001522127	123274217	123274286
ENSE00002138192	123248456	123250320
ENSE00002184971	123267273	123267386

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 96.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.4068 / max 61.1321, expressed in 1560 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
94711	8.9741	1665
94715	3.8827	1425
94713	0.9118	522
94714	0.3855	189
94712	0.2268	88

Top tissues by expression

262 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	96.18	gold quality
secondary oocyte	CL:0000655	96.17	gold quality
oocyte	CL:0000023	95.97	gold quality
kidney epithelium	UBERON:0004819	95.85	gold quality
calcaneal tendon	UBERON:0003701	95.59	gold quality
epithelium of mammary gland	UBERON:0003244	95.56	gold quality
mammary duct	UBERON:0001765	95.55	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.50	gold quality
cerebellar vermis	UBERON:0004720	95.41	gold quality
medial globus pallidus	UBERON:0002477	95.20	gold quality
medulla oblongata	UBERON:0001896	95.09	gold quality
globus pallidus	UBERON:0001875	95.05	gold quality
superior vestibular nucleus	UBERON:0007227	95.05	gold quality
penis	UBERON:0000989	95.00	gold quality
lateral globus pallidus	UBERON:0002476	94.98	gold quality
corpus callosum	UBERON:0002336	94.70	gold quality
pigmented layer of retina	UBERON:0001782	94.56	gold quality
retina	UBERON:0000966	94.53	gold quality
substantia nigra pars compacta	UBERON:0001965	94.40	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.39	gold quality
subthalamic nucleus	UBERON:0001906	94.32	gold quality
parotid gland	UBERON:0001831	94.31	gold quality
pharyngeal mucosa	UBERON:0000355	94.27	gold quality
trigeminal ganglion	UBERON:0001675	94.25	gold quality
ganglionic eminence	UBERON:0004023	94.25	gold quality
embryo	UBERON:0000922	94.24	gold quality
ventral tegmental area	UBERON:0002691	94.01	gold quality
gingival epithelium	UBERON:0001949	93.72	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.66	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.56	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.06
E-GEOD-106540	no	448.80
E-MTAB-7606	no	199.48

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
ZHX1

Upstream regulators (CollecTRI, top): ETV4, YY1, ZHX1

miRNA regulators (miRDB)

185 targeting ZHX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505

Literature-anchored findings (GeneRIF, showing 12)

• This study characterized features of ZHX-1 involved in nuclear localization, dimerization, and transcriptional activity, and mapped these domains. (PMID:12237128)
• a search of ZHX1-interacting proteins using a yeast two-hybrid system (PMID:12659632)
• ZHX proteins 1, 2 and 3 are major transcriptional mediators of podocyte disease (PMID:17056598)
• ZHX1 enhanced the transcriptional repression mediated by DNMT3B when DNMT3B is directly targeted to DNA. These results showed for the first the direct linkage between DNMT and zinc-fingers homeoboxes protein, leading to enhanced gene silencing by DNMT3B (PMID:17303076)
• structure of the tandem zinc-finger region of human ZHX1 (PMID:19348505)
• Study showed that ZHX1 is SUMOylated by Ubc9 with SUMO1 at the sites K159, K454, and K626 and that the SUMOylation of ZHX1 regulated the stability, ubiquitination and transcriptional activity of ZHX1. (PMID:23686912)
• Low expression of ZHX1 may be responsible for hepatocarcinogenesis. (PMID:24064680)
• High-quality solution NMR structures of three homeodomains from human proteins ALX4, ZHX1 and CASP8AP2 were solved. (PMID:24941917)
• miR-199a-3p may function as a novel tumor promoter in gastric cancer and its oncogenic activity may involve the direct targeting and inhibition of ZHX1 (PMID:25448600)
• ZHX1 was found to play essential roles in the proliferation, migration, and invasion of cholangiocarcinoma cells, and its effect on the proliferation was mediated partially through EGR1. (PMID:27835650)
• ZHX1 expression is correlated with renal cell carcinoma progression and poor survival. (PMID:28152006)
• together, this study demonstrates that ZHX1 plays crucial roles in the progression of glioblastoma, and its findings suggest that ZHX1 be viewed as a potential prognostic maker and therapeutic target of glioblastoma. (PMID:28351300)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zhx1	ENSMUSG00000022361
rattus_norvegicus	Zhx1	ENSRNOG00000006412

Paralogs (3): ZHX3 (ENSG00000174306), ZHX2 (ENSG00000178764), HOMEZ (ENSG00000290292)

Protein

Protein identifiers

Zinc fingers and homeoboxes protein 1 — Q9UKY1 (reviewed: Q9UKY1)

All UniProt accessions (2): Q9UKY1, U3KPX4

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a transcriptional repressor. Increases DNMT3B-mediated repressive transcriptional activity when DNMT3B is tethered to DNA. May link molecule between DNMT3B and other co-repressor proteins.

Subunit / interactions. Forms homodimers. Heterodimer (via HD1 domain) with ZHX2 (via HD1 domain). Also forms a heterodimer with ZHX3 which is a prerequisite for repressor activity. Interacts with ATF7IP and NFYA. Interacts (via homeobox domains) with DNMT3B (via PWWP domain).

Subcellular location. Nucleus.

Tissue specificity. Ubiquitously expressed. Expressed in podocytes.

Similarity. Belongs to the ZHX family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UKY1-1	1	yes
Q96EF9-1	2, ZHX1-C8orf76

RefSeq proteins (2): NP_001017926, NP_009153* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR024578	Homez_homeobox_dom	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR041057	ZHX_Znf_C2H2	Domain

Pfam: PF00046, PF11569, PF18387

UniProt features (60 total): helix 13, region of interest 9, modified residue 7, strand 7, compositionally biased region 5, cross-link 5, DNA-binding region 5, turn 4, zinc finger region 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
3NAR	X-RAY DIFFRACTION	2.6
2ECB	SOLUTION NMR
2GHF	SOLUTION NMR
2LY9	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKY1-F1	62.10	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 36, 45, 47, 48, 202, 648, 774, 159, 441, 454, 485, 629

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 145 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GCM_ZNF198, GCM_PPM1D, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, ATTCTTT_MIR186, TAATGTG_MIR323, CUI_TCF21_TARGETS_2_DN, HOXA4_Q2, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON, GOMF_PROTEIN_HETERODIMERIZATION_ACTIVITY, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, HAMAI_APOPTOSIS_VIA_TRAIL_UP, GCTCTTG_MIR335

GO Biological Process (4): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), cell differentiation (GO:0030154), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (7): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
cellular developmental process	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
protein dimerization activity	1
binding	1
cation binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1

Protein interactions and networks

STRING

644 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZHX1	NFYA	P23511	938
ZHX1	DNMT3B	Q9UBC3	721
ZHX1	NFYC	Q13952	713
ZHX1	NFYB	P25208	614
ZHX1	ZMYND11	Q15326	577
ZHX1	HOXC8	P31273	568
ZHX1	CDC25C	P30307	488
ZHX1	MYC	P01106	473
ZHX1	MED21	Q13503	450
ZHX1	USF2	Q15853	439
ZHX1	CREB1	P16220	393
ZHX1	KPNA2	P52292	390
ZHX1	HOMEZ	Q8IX15	377
ZHX1	ATF6B	Q99941	375
ZHX1	DHX35	Q9H5Z1	354

IntAct

119 interactions, top by confidence:

A	B	Type	Score
RIOK1	PRMT5	psi-mi:“MI:0914”(association)	0.710
ATXN1	ZHX1	psi-mi:“MI:0915”(physical association)	0.700
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
ZHX1	DNMT3B	psi-mi:“MI:0915”(physical association)	0.610
ZHX1	DNMT3B	psi-mi:“MI:0403”(colocalization)	0.610
DNMT3B	ZHX1	psi-mi:“MI:0407”(direct interaction)	0.610
ZHX1	DNMT3B	psi-mi:“MI:0407”(direct interaction)	0.610
ZHX1	ZHX2	psi-mi:“MI:0915”(physical association)	0.590
ZMYND11	ZHX1	psi-mi:“MI:0407”(direct interaction)	0.590
ZHX1	ZMYND11	psi-mi:“MI:0915”(physical association)	0.590
YY1	YY2	psi-mi:“MI:0914”(association)	0.570
HTT	ZHX1	psi-mi:“MI:0915”(physical association)	0.560
WDR83	SH2B2	psi-mi:“MI:0914”(association)	0.530
UBE2I	ZHX1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (134): UBE2I (Two-hybrid), ZHX1 (Affinity Capture-Western), UBE2I (Affinity Capture-Western), ZHX1 (Affinity Capture-MS), ZHX1 (Affinity Capture-MS), ZHX2 (Affinity Capture-MS), ZHX1 (Affinity Capture-MS), ZHX1 (Affinity Capture-MS), ZHX1 (Proximity Label-MS), ZHX1 (Two-hybrid), ZMYND11 (Two-hybrid), ATXN1 (Two-hybrid), EFNA2 (Two-hybrid), ELL (Two-hybrid), ZHX1 (Two-hybrid)

ESM2 similar proteins: A1YF22, A1YG99, A2T771, A2T7S4, B3DJM5, D3ZKB9, H2L008, O42410, O73590, P34303, P70121, Q03112, Q15652, Q15723, Q19418, Q21502, Q24478, Q2HNT1, Q2HNT2, Q2TB10, Q3UG20, Q58F21, Q5DTH5, Q5R7F2, Q5RCU4, Q61SK8, Q63HK5, Q66J63, Q69ZW3, Q6GN21, Q6P2L6, Q6ZSZ6, Q80VX4, Q86MI0, Q86T24, Q86UP3, Q8BN78, Q8C0C0, Q8CGV9, Q8IZD2

Diamond homologs: A1YF22, A1YG99, A2T771, A2T7S4, P70121, Q5R7F2, Q80VX4, Q80Z36, Q8C0C0, Q8C0Q2, Q8IX15, Q8R515, Q9H4I2, Q9UKY1, Q9Y6X8, Q80W88, Q8K3E9, Q61321, Q9UIU6

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
ZHX1	“down-regulates activity”	ZMYND11	binding
UBE2I	“up-regulates quantity by stabilization”	ZHX1	sumoylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 100 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of TP53 Activity through Acetylation	5	30.4×	3e-04
KEAP1-NFE2L2 pathway	7	11.2×	8e-04

GO biological processes:

GO term	Partners	Fold	FDR
cellular response to retinoic acid	5	12.7×	4e-03
chromatin remodeling	10	7.9×	8e-05
transcription by RNA polymerase II	8	6.1×	4e-03
positive regulation of apoptotic process	9	5.5×	3e-03
positive regulation of gene expression	10	4.2×	8e-03
negative regulation of apoptotic process	11	4.2×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

786 predictions. Top by Δscore:

Variant	Effect	Δscore
8:123250318:CAG:C	acceptor_gain	1.0000
8:123250321:C:CC	acceptor_gain	1.0000
8:123267271:A:AC	donor_gain	1.0000
8:123267272:C:CC	donor_gain	1.0000
8:123267274:TGCC:T	donor_gain	1.0000
8:123267284:T:TA	donor_gain	1.0000
8:123269030:T:A	donor_gain	1.0000
8:123250138:T:TA	donor_gain	0.9900
8:123250138:TCC:T	donor_gain	0.9900
8:123250320:GC:G	acceptor_loss	0.9900
8:123267273:TTGC:T	donor_gain	0.9900
8:123274125:T:A	donor_gain	0.9900
8:123250122:T:C	donor_gain	0.9800
8:123250127:A:C	donor_gain	0.9800
8:123250316:GGCAG:G	acceptor_gain	0.9800
8:123250317:GCAG:G	acceptor_gain	0.9800
8:123250318:CAGC:C	acceptor_gain	0.9800
8:123250319:AG:A	acceptor_gain	0.9800
8:123253320:A:AC	donor_gain	0.9800
8:123253321:C:CC	donor_gain	0.9800
8:123267290:G:C	donor_gain	0.9800
8:123267387:C:CC	acceptor_gain	0.9800
8:123250137:TTC:T	donor_gain	0.9700
8:123253321:CATTT:C	donor_gain	0.9700
8:123267272:CTTG:C	donor_gain	0.9700
8:123250159:A:C	donor_gain	0.9600
8:123250319:A:T	acceptor_gain	0.9600
8:123253321:CATT:C	donor_gain	0.9600
8:123267275:G:A	donor_gain	0.9600
8:123267386:CCTA:C	acceptor_loss	0.9600

AlphaMissense

5783 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:123253494:A:G	F818S	1.000
8:123253498:A:G	W817R	1.000
8:123253498:A:T	W817R	1.000
8:123253506:A:T	V814D	1.000
8:123253539:A:G	L803P	1.000
8:123253548:A:G	L800P	1.000
8:123253593:A:G	L785P	1.000
8:123253593:A:T	L785H	1.000
8:123253781:C:A	W722C	1.000
8:123253781:C:G	W722C	1.000
8:123253783:A:G	W722R	1.000
8:123253783:A:T	W722R	1.000
8:123253812:C:G	R712P	1.000
8:123253813:G:T	R712S	1.000
8:123253823:A:C	F708L	1.000
8:123253823:A:T	F708L	1.000
8:123253824:A:G	F708S	1.000
8:123253825:A:G	F708L	1.000
8:123253828:A:G	W707R	1.000
8:123253828:A:T	W707R	1.000
8:123253893:G:T	P685Q	1.000
8:123253910:A:C	F679L	1.000
8:123253910:A:T	F679L	1.000
8:123253912:A:G	F679L	1.000
8:123253919:C:A	K676N	1.000
8:123253919:C:G	K676N	1.000
8:123253923:A:G	L675P	1.000
8:123253923:A:T	L675H	1.000
8:123254127:A:G	L607P	1.000
8:123254399:C:A	R516S	1.000

dbSNP variants (sampled 300 via entrez): RS1000020950 (8:123272139 C>T), RS1000074255 (8:123258737 T>C), RS1000194978 (8:123269329 C>T), RS1000208535 (8:123276385 G>A,T), RS1000245260 (8:123273453 G>A), RS1000351038 (8:123275735 C>T), RS1000461655 (8:123251151 G>T), RS1000640549 (8:123267943 G>C), RS1000664087 (8:123276131 T>C), RS1000691396 (8:123267626 C>T), RS1000794212 (8:123258439 G>A,C), RS1000887800 (8:123258124 C>A,T), RS1000935091 (8:123261563 G>A), RS1001007443 (8:123264714 C>A,G,T), RS1001039128 (8:123254250 T>A)

Disease associations

OMIM: gene MIM:604764 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression	3
sodium arsenite	decreases expression, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Tretinoin	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	decreases expression, affects cotreatment	2
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression, increases expression	1
methylparaben	decreases expression	1
coumarin	increases phosphorylation	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Diazinon	increases methylation	1
Estradiol	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Thiram	decreases expression	1
Cyclosporine	decreases expression	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.